Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Repadina Plus
- Development stage
- Unknown
- Lead developer
- Norgine
- Administration
- Vaginal
01
Overview
Repadina Plus is a hormone-free vaginal pessary developed and marketed by Norgine Pharmaceuticals. It is classified as a medical device used to treat vaginal dryness (atrophic vaginitis) and promote the healing of the vaginal mucosa. The formulation combines sodium hyaluronate, a naturally occurring polysaccharide that binds water to provide long-lasting hydration and support tissue regeneration, with sweet almond oil, which acts as an emollient to lubricate and soothe the vaginal lining. It is commonly used by women experiencing dryness due to menopause, breastfeeding, or following gynecological procedures and childbirth.
- Brand names
- Repadina Plus
- Other names
- Repadina
Beyond the preview
Go deeper on Repadina Plus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Repadina Plus.